Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Informatics tools can identify precision medicine opportunities in DLBCL

Publish date:: June 11, 2020

Key clinical point: Determining mutations can provide outcomes prediction, therapy targets.

Major finding: Twenty-two targetable mutations present in ≥ 5% of patients with DLBCL were associated with unfavorable outcomes.

Study details: Informatics assessment of primary sequencing data for DLBCL-related mutations and their association with signaling pathways, cell-of-origin subtypes, and clinical outcomes.

Disclosures: The present study was supported by the National Institutes of Health, The author reported research and consulting fees from a variety of pharmaceutical companies.

Citation:

Patel SP et al. Clinical Lymphoma, Myeloma & Leukemia 2020;20(4):234-43.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,